---
title: "ImmuneOnco Biopharma files HKEX next-day disclosure return on share buyback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291925261.md"
description: "ImmuneOnco Biopharma filed a next-day disclosure with the HKEX regarding a share buyback on July 7, 2026. The company repurchased 91,800 H shares on-market at prices ranging from HKD 3.57 to HKD 3.86 per share, totaling an aggregate consideration of HKD 337,936. No shares were cancelled in this transaction."
datetime: "2026-07-07T11:33:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291925261.md)
  - [en](https://longbridge.com/en/news/291925261.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291925261.md)
---

# ImmuneOnco Biopharma files HKEX next-day disclosure return on share buyback

-   ImmuneOnco filed a next-day disclosure return to HKEX reporting a repurchase of 91,800 H shares on July 7, 2026. \* Shares were bought on-market at HKD 3.57 to HKD 3.86 each; aggregate consideration HKD 337,936. \* Total repurchased or cancelled shares: 91,800 repurchased; 0 cancelled. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260707-12236879), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01541.HK](https://longbridge.com/en/quote/01541.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [ImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection](https://longbridge.com/en/news/295160557.md)
- [ImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection](https://longbridge.com/en/news/290219823.md)
- [07:20 ETAizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics](https://longbridge.com/en/news/296000080.md)
- [I stared deep into the heart of LinkedIn AI cringe slop. Darkness (and engagement) stared back.](https://longbridge.com/en/news/295998393.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)